Is Capd Atherogenic?

Raine A.E.G. The EDTA Registry Committee. Combined report on regular dialysis and transplantation in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 2: 7–35.

US Renal Data System (USRDS) 1991. Annual data report. Survival probabilities and causes of death. Bethesda, MD: National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 1991: 31–40.

Churchill D.N. , Taylor W. , Cook R.J. Canadian hemodialysis morbidity study. Am J Kidney Dis 1992; 19: 214–34.

Bloembergen W.E. , Port F.K. , Mauger E.A. , Wolfe R.A. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6: 177–83.

Bloembergen W.E. , Port F.K. , Mauger E.A. , Wolfe R.A. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6: 184–91.

Maiorca R. , Vonesh E.F. , Cancarini G.C. A six-year comparison of patient and technique survivals in CAPD and HD. Kidney Int 1988; 34: 518–24.

Maiorca R. , Vonesh E.F. , Cavalli P. A multicenter, selection-adjusted comparison of patient and technique survivals on CAPD and hemodialysis. Perit Dial Int 1991; 11: 118–27.

Gentil M.A. , Carriazo A. , Pavon M.I. Comparison of survival in continuous ambulatory peritoneal dialysis and hospital hemodialysis: a multicentric study. Nephrol Dial Tran.splant 1991; 6: 444–51.

Burton P.R. , Walls J. Selection-adjusted comparison of life-expectancy of patients on continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation. Lancet 1987; 1: 1115–18.

Fenton S.D. Renal replacement therapy in Canada 1981–1992. In: Replacement of renal function by dialysis. 4th ed. Jacobs C. , Kjellstrand C.M. , Koch K.M. , Winchester J.F. , eds. Kluwer Academic: Dordrecht, 1996: 1406–22.

Attman P. , Samuelsson O. , Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Di.s 1993; 21: 573–92.

Avram M.M. , Goldwasser P. , Burrell D.E. , Antignani A. , Fein P.A. , Mittman N. The uremic dysli pidemia: a cross sectional and longitudinal study. Am J Kidney Di.s 1992; 20: 324–35.

Elisaf M. , Mikhailidis D.P. , Siamopoulos K.C. Dys lipidemia in patients with renal diseases. J Drug Dev Clin Pract 1996; 7: 331–48.

Chan M.K. , Persaud J. , Varghese Z. , Moorhead J.F. Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int 1984; 25: 812–18.

Guanieri G.F. , Morcchiello M. , Campanacci L. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int 1978; 13(Suppl 8): S26–30.

Chan M.K. , Varghese Z. , Persaud J.W. , Baillod R.A. , Moorhead J.F. Hyperlipidemia in patients on maintenance hemo and peritoneal dialysis: the relative pathogenetic roles of triglyceride production and triglyceride removal. Clin Nephrol 1982; 17: 183–90.

A vram M.M. , Fein P.A. , Antignani A. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med 1989: 87(Suppl 5N): 5–55N.

Frank W.M. , Rao T.K.S. , Manis T. Relationship of plasma lipids to renal function and length of time on maintenance hemodialysis. Am J Clin Nutr 1978; 31: 1886–92.

Haas L.B. , Wah I.P.W. , Sherrard D.J. A longitudinal study of lipid abnormalities in renal failure. Nephron 1983; 22: 145–9.

Kagan A. , Bar-Khayim Y. , Schafer Z. , Fainaru M. Kinetics of peritoneal protein loss during CAPD. Part II: Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 1990; 37: 980–90.

Ramos J.M. , Heaton A. , McGurk J.G. , Ward M.L. , Kerr D.N.S. Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis. Nephron 1983; 35: 20–3.

Lindholm B. , Norbeck H.E. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 1986; 220: 143–51.

Breckenridge W.C. , Roncari D.A.K. , Khanna R. , Oreopoulos D.G. The influence of continuous ambulatory peritoneal dialysis on plasma lipoproteins. Atherosclerosis 1982; 45: 249–58.

Sniderman A. , Cianflone K. , Kwiterovich P.O. , Hutchinson T. , Barre P. , Prichard S. Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. Atherosclerosis 1987; 65: 257–64.

Llopart R. , Donate T. , Oliva J.A. Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. Nephrol Dial Transplant 1995; 10: 537–40.

Horkko S. , Huttunen K. , Laara E. , Kervinen K. , Kesaniemi Y.A. Effects of 3 treatment modes on plasma lipids and lipoproteins in uremic patients. Ann Med 1994; 26: 271–82.

Siamopoulos K.C. , Elisaf M.S. , Bairaktari T.H. , Pappas M.B. , Sferopoulos G.D. , Nikolakakis N.G. Lipid parameters including lipoprotein(a) in patients undergoing CAPD and hemodialysis. Perit Dial Int 1995; 15: 342–7.

Massy Z.A. , Ma J.Z. , Louis T.A. , Kasiske B.L. Lipid-Iowering therapy in patients with renal disease. Kidney Int 1995; 48: 188–98.

Levine D.M. , Gordon B.R. Lipoprotein (a) levels in patients receiving renal replacement therapy: methodologic issues and clinical implications. Am J Kidney Dis 1995; 26: 162–9.

Eggertsen G. , Heillbürger O. , Stenvinkel P. , Berglund L. Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients. Nephrol Dial Transplant 1997; 12: 141–4.

Wheeler D.C. Abnormalities of lipoprotein metabolism in CAPD patients. Kidney Int 1996; 50(Suppl 56): S41–6.

Heimbürger O. , Stenvinkel P. , Berglund L. , Tranaeus A. , Lindholm B. Increased plasma lipoprotein (a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron 1996; 72: 135–44.

Wanner C. , Bartens W. , Walz G. , Nauck M. , Schollmeyer P. Protein loss and genetic polymorphism of apolipoprotein (a) modulate serum lipoprotein (a) in CAPD patients. Nephrol Dial Transplant 1995; 10: 75–81.

Kagan A. , Var-Khayim Y. , Schafer Z. , Fainaru M. Heterogeneity in peritoneal transport during continuous ambulatory peritoneal dialysis and its impact on ultrafiltration, loss of macromolecules and plasma level of proteins, lipids and lipoproteins. Nephron 1993; 63: 32–43.

Saku K. , Sasaki J. , Naito S. , Arakawa K. Lipoprotein and apolipoprotein losses during continuous ambulatory peritoneal dialysis. Nephron 1989; 51: 220–4.

Kandoussi A. , Cachera C. , Reade R. , Pagniez D. , Fruchart J.C. , Tacquet A. Apo AIV in plasma and dialysate fluid of CAPD patients: comparison with other apoproteins. Nephrol Dial Transplant 1992; 7: 1026–9.

Dieplinger H. , Schoenfeld P.Y. , Fielding C.J. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis. J Clin Invest 1986; 77: 1071–83.

Corboy J. , Sutherland W.H. , Walker R.J. , Robertson M.C. , Cox C.M. Cholesterol ester transfer in patients with renal failure or renal transplants. Kidney Int 1994; 46: 1147–53.

Castelli W.P. , Garrison R.J. , Wilson P.W.F. , Abbott R.D. , Kalousdian S. , Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835–8.

Sillons L.A. Interrelations of lipids and lipoproteins with coronary heart disease mortality in 19 countries. Am J Cardiol 1986; 57: 5–10G.

Rosengern A. , Wilhelrosen L. , Eriksson E. , Risberg B. , Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in general population sample of middle aged men. Br Med J 1990; 301: 1248–51.

Slyper R.W. A fresh look at the atherogenic remnant hypothesis. Lancet 1992; 340: 289–91.

Webb A.T. , Reaveley D.A. , O'Donell M. , O'Connor B. , Seed M. , Brown E.A. Lipids and lipoprotein (a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 1994; 5: 354–7.

Bartens W. , Nauch M. , Schollmeyer P. , Wanner C. EI evated lipoprotein(a) and fibrinogen serum levels increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1996; 16: 27–33.

Gault M.H. , Longerich L.L. , Purchase L. , Harnett J. , Breckenridge C. Comparison of Lp(a) concentrations and some potential effects in hellodiaysis, CAPD, transplantation, and control groups, and review of the literature. Nephron 1995; 70: 155–70.

Piccoli G.B. , Quarello F. , Salomone M. Are serum albumin and cholesterol reliable outcome markers in elderly dialysis patients? Nephrol Dial Tran.splant 1995; 10(Suppl 6): 72–7.

Ritz E. Why are lipids not predictive of cardiovascular death in the dialysis patient? Miner Electrolyte Metab 1996; 22: 9–12.

Attman P.O. , Alaupovic P. , Gustafson A. Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 1987; 32: 368–75.

Chan M.K. Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions. Metabolism 1989; 38: 939–45.

Elisaf M.S. , Dardamanis M.A. , Papagalanis N.D. , Siamopoulos K.C. Lipid abnormalities in chronic uremic patients. Scand J Urol Nephrol 1993; 27: 101–8.

Chan M.K. Sustained release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis. Nephron 1990; 56: 56–61.

Wanner C. , Lubrich-Birkner I. , Summ O. , Wieland H. , Schollmeyer P. Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients. Nephron 1992; 62: 40–6.

Dimitriadis A. , Antoniou S. , Hatzisavvas N. , Pastore F. , Kaldi I. , Stangou M. The effect of simvastatin on dyslipidemia in continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13(Suppl 2): S434–6.

Li P.K.T. , Mak T.W.L. , Lam C.W.K. , Kai K.N. Lovastatin treatment of dyslipoproteinemia in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13(Suppl 2): S428–30.

Nishizawa Y. , Shoji T. , Nishitani H. Hypertri-glyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: effect of a fibric acid, clinofibrate. Kidney Int 1993; 44(6): 1352–9.

Nishizawa Y. , Shoji T. , Emoto M. Reduction of intermediate density lipoprotein by pravastatin in hemo and peritoneal dialysis patients. Clin Nephrol 1995; 43: 268–77.

Walker R.J. , Sutherland W.H.F. , Walker H.L. , MacMahon S. , Robson R.A. Effect of treatment with simvastatin on serum cholesterol ester transfer in patients on dialysis. Nephrol Dial Tran,splant 1997; 12: 87–92.

Van Acker B.A.C. , Bilo H.J.G. , Popp-Snijders C. , Van Bronswijk H. , Oe L.P. , Donker A.J.M. The effects of fish oil on lipid profile and viscosity of erythrocyte suspensions in CAPD patients. Nephrol Dial Transplant 1987; 2: 557–61.

Jones R.G. , Dibble K.B. , Gibson J. Effect of dietary fish oil on lipid abnormalities in CAPD patients. Perit Dial Bull 1988; 8: 203–26.

Lempert K.D. , Rogers J.S. , Albrinck M.J. Effects of dietary fish oil on serum lipids an d blood coagulation in peritoneal dialysis patients. Am J Kidney Dis 1988; 11: 170–5.

Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequancy of dialysis and nutrition in continuous peritoneal dialysis: association with clinica] outcomes. J Am Soc Nephrol 1996; 7: 198–207.